Herpes Zoster News and Research

RSS
Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Pain, itching associated with shingles may be due to virus causing "short circuit" in nerve cells

Pain, itching associated with shingles may be due to virus causing "short circuit" in nerve cells

Emergency physicians correctly identify nearly 100% of patients with Bell's palsy

Emergency physicians correctly identify nearly 100% of patients with Bell's palsy

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

New study shows varicella vaccine neutralizes chicken pox

New study shows varicella vaccine neutralizes chicken pox

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

RA patients who initiate anti-TNF therapies do not have higher risk of shingles: Study

RA patients who initiate anti-TNF therapies do not have higher risk of shingles: Study

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Patients with untreated depression are poorly protected by shingles vaccination

Patients with untreated depression are poorly protected by shingles vaccination

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Population Health Management discusses latest information on shingles and PHN

Population Health Management discusses latest information on shingles and PHN

Shingles vaccine reduces risk of herpes zoster disease in older patients

Shingles vaccine reduces risk of herpes zoster disease in older patients

Shingles becoming more common in Australia

Shingles becoming more common in Australia

Broad spectrum sunscreens needed to block UVB and UVA

Broad spectrum sunscreens needed to block UVB and UVA

Cancer fears allayed for shingles patients

Cancer fears allayed for shingles patients

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma